MERTK
Tyrosine-protein kinase Mer
As of the edition of 20 October 2026, MERTK (tyrosine-protein kinase Mer, UniProt Q12866) has 5 drugs tested at it and 6 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q12866
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 43
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Heart and blood vessels; Immune system; Hormones; Infections
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 3 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ningetinib | Stopped | Phase 2 | none listed |
| Tamnorzatinib | Active | Phase 2 | none listed |
| INCB081776 | Stopped | Phase 1 | none listed |
| Zevorcabtagene autoleucel | Active | No phase stated | none listed |
| PF-07265807 | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Incyte | Route A |
| Pfizer | Route A |
| Jiangsu Alphamab Biopharmaceuticals | Route A |
The other 3 companies at MERTK
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at MERTK, ranked, with the facts behind eachRequest access. Nothing is shown until you do.